Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Abcellera Biologics Inc (ABCL)
Abcellera Biologics Inc (ABCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,425,849
  • Shares Outstanding, K 292,782
  • Annual Sales, $ 485,420 K
  • Annual Income, $ 158,520 K
  • 60-Month Beta 0.38
  • Price/Sales 37.34
  • Price/Cash Flow N/A
  • Price/Book 1.22
Trade ABCL with:

Options Overview Details

View History
  • Implied Volatility 59.74% ( -7.51%)
  • Historical Volatility 62.37%
  • IV Percentile 18%
  • IV Rank 7.79%
  • IV High 228.67% on 11/03/23
  • IV Low 45.47% on 09/14/23
  • Put/Call Vol Ratio 0.71
  • Today's Volume 24
  • Volume Avg (30-Day) 283
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 22,013
  • Open Int (30-Day) 20,908

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.16
  • Number of Estimates 5
  • High Estimate -0.12
  • Low Estimate -0.25
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.65 +3.33%
on 02/21/24
5.62 -14.50%
on 01/29/24
-0.52 (-9.68%)
since 01/26/24
3-Month
4.27 +12.53%
on 11/27/23
6.05 -20.64%
on 01/08/24
+0.38 (+8.47%)
since 11/24/23
52-Week
3.87 +24.16%
on 10/30/23
8.63 -44.32%
on 02/28/23
-3.57 (-42.59%)
since 02/24/23

Most Recent Stories

More News
AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript

ABCL earnings call for the period ending December 31, 2023.

ABCL : 4.86 (-0.21%)
4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond

Healthcare stocks have underperformed in 2023, but that is expected to change this year.

CNC : 80.79 (+0.71%)
HALO : 39.83 (-1.80%)
ABCL : 4.86 (-0.21%)
HUM : 361.22 (-0.47%)
3 Growth Stocks That Could Go Parabolic in 2024

These innovation-oriented companies could take flight this year.

ABCL : 4.86 (-0.21%)
CERS : 2.24 (+1.36%)
TSHA : 2.36 (-5.60%)
AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript

ABCL earnings call for the period ending September 30, 2023.

ABCL : 4.86 (-0.21%)
Argenx's 28% Surge & Promising Product Propel Investor Confidence

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

ARGX : 408.59 (-0.23%)
ABBV : 178.53 (+0.25%)
ABCL : 4.86 (-0.21%)
ALNY : 155.67 (-1.26%)
AMGN : 286.29 (-1.00%)
ANAB : 26.99 (+4.33%)
AZN : 65.78 (-0.08%)
BMY : 51.10 (-1.08%)
INCY : 60.44 (-0.25%)
REGN : 976.94 (-0.43%)
VIE : 53.01 (unch)
AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript

ABCL earnings call for the period ending June 30, 2023.

ABCL : 4.86 (-0.21%)
AbCellera Biologics (ABCL) Q1 2023 Earnings Call Transcript

ABCL earnings call for the period ending March 31, 2023.

ABCL : 4.86 (-0.21%)
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Tops Revenue Estimates

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -16.67% and 6.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

ABCL : 4.86 (-0.21%)
PIRS : 0.1615 (-0.68%)
AbCellera Reports Q1 2023 Business Results

AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2023. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

ABCL : 4.86 (-0.21%)
How AI Is Revolutionizing Tech, and Why You Should Invest in These Leading Companies

Check out these compelling opportunities.

ABBV : 178.53 (+0.25%)
ABCL : 4.86 (-0.21%)
ISRG : 388.28 (-0.38%)
MSFT : 409.34 (-0.24%)
AMZN : 175.21 (+0.13%)
NET : 99.81 (+1.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AbCellera Biologics Inc. is a technology company which searches, decodes and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera Biologics Inc. is based in Vancouver, Canada.

See More

Key Turning Points

3rd Resistance Point 5.29
2nd Resistance Point 5.19
1st Resistance Point 5.03
Last Price 4.86
1st Support Level 4.76
2nd Support Level 4.66
3rd Support Level 4.50

See More

52-Week High 8.63
Fibonacci 61.8% 6.81
Fibonacci 50% 6.25
Fibonacci 38.2% 5.69
Last Price 4.86
52-Week Low 3.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar